These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22763024)

  • 1. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients.
    Solas M; Francis PT; Franco R; Ramirez MJ
    Neurobiol Aging; 2013 Mar; 34(3):805-8. PubMed ID: 22763024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex.
    Lee JH; Agacinski G; Williams JH; Wilcock GK; Esiri MM; Francis PT; Wong PT; Chen CP; Lai MK
    Neurochem Int; 2010 Dec; 57(8):985-9. PubMed ID: 21034788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
    Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
    J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes of nuclear factor and inflammatory chemotactic factors in brain of patients with Alzheimer's disease].
    Liao Y; Guan ZZ; Ravid R
    Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):585-9. PubMed ID: 22177240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of CB
    Wu J; Hocevar M; Foss JF; Bie B; Naguib M
    Eur J Pharmacol; 2017 Sep; 811():12-20. PubMed ID: 28551012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease.
    Koppel J; Vingtdeux V; Marambaud P; d'Abramo C; Jimenez H; Stauber M; Friedman R; Davies P
    Mol Med; 2014 Mar; 20(1):29-36. PubMed ID: 24722782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains.
    Zeppenfeld DM; Simon M; Haswell JD; D'Abreo D; Murchison C; Quinn JF; Grafe MR; Woltjer RL; Kaye J; Iliff JJ
    JAMA Neurol; 2017 Jan; 74(1):91-99. PubMed ID: 27893874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer's Brain Tissue.
    Ni R; Röjdner J; Voytenko L; Dyrks T; Thiele A; Marutle A; Nordberg A
    J Alzheimers Dis; 2021; 80(4):1723-1737. PubMed ID: 33749648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CB₂ receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease.
    Koppel J; Vingtdeux V; Marambaud P; d'Abramo C; Jimenez H; Stauber M; Friedman R; Davies P
    Mol Med; 2013 Nov; 19(1):357-64. PubMed ID: 24408112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway.
    Fakhfouri G; Ahmadiani A; Rahimian R; Grolla AA; Moradi F; Haeri A
    Neuropharmacology; 2012 Sep; 63(4):653-66. PubMed ID: 22634229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyroglutamylated amyloid-β is associated with hyperphosphorylated tau and severity of Alzheimer's disease.
    Mandler M; Walker L; Santic R; Hanson P; Upadhaya AR; Colloby SJ; Morris CM; Thal DR; Thomas AJ; Schneeberger A; Attems J
    Acta Neuropathol; 2014 Jul; 128(1):67-79. PubMed ID: 24861310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.
    Aso E; Andrés-Benito P; Carmona M; Maldonado R; Ferrer I
    J Alzheimers Dis; 2016; 51(2):489-500. PubMed ID: 26890764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid Receptor 2-Deficiency Ameliorates Disease Symptoms in a Mouse Model with Alzheimer's Disease-Like Pathology.
    Schmöle AC; Lundt R; Toporowski G; Hansen JN; Beins E; Halle A; Zimmer A
    J Alzheimers Dis; 2018; 64(2):379-392. PubMed ID: 29865078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble amyloid beta levels are elevated in the white matter of Alzheimer's patients, independent of cortical plaque severity.
    Collins-Praino LE; Francis YI; Griffith EY; Wiegman AF; Urbach J; Lawton A; Honig LS; Cortes E; Vonsattel JP; Canoll PD; Goldman JE; Brickman AM
    Acta Neuropathol Commun; 2014 Aug; 2():83. PubMed ID: 25129614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB
    Navarro G; Borroto-Escuela D; Angelats E; Etayo Í; Reyes-Resina I; Pulido-Salgado M; Rodríguez-Pérez AI; Canela EI; Saura J; Lanciego JL; Labandeira-García JL; Saura CA; Fuxe K; Franco R
    Brain Behav Immun; 2018 Jan; 67():139-151. PubMed ID: 28843453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease.
    Ikonomovic MD; Wecker L; Abrahamson EE; Wuu J; Counts SE; Ginsberg SD; Mufson EJ; Dekosky ST
    Arch Neurol; 2009 May; 66(5):646-51. PubMed ID: 19433665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains.
    Benito C; Núñez E; Tolón RM; Carrier EJ; Rábano A; Hillard CJ; Romero J
    J Neurosci; 2003 Dec; 23(35):11136-41. PubMed ID: 14657172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo type 1 cannabinoid receptor availability in Alzheimer's disease.
    Ahmad R; Goffin K; Van den Stock J; De Winter FL; Cleeren E; Bormans G; Tournoy J; Persoons P; Van Laere K; Vandenbulcke M
    Eur Neuropsychopharmacol; 2014 Feb; 24(2):242-50. PubMed ID: 24189376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prion protein is decreased in Alzheimer's brain and inversely correlates with BACE1 activity, amyloid-β levels and Braak stage.
    Whitehouse IJ; Miners JS; Glennon EB; Kehoe PG; Love S; Kellett KA; Hooper NM
    PLoS One; 2013; 8(4):e59554. PubMed ID: 23577068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer's Disease.
    Talarico G; Trebbastoni A; Bruno G; de Lena C
    Curr Neuropharmacol; 2019; 17(2):176-183. PubMed ID: 29962346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.